Page 5 - Neil Kumar News Today

BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Rating) CFO Brian C. Stephenson sold 24,424 shares of the firm’s stock in a transaction on Wednesday, May 17th. The shares were sold at an average price of $14.01, for a total transaction of $342,180.24. Following the sale, the chief financial officer now owns 36,408 shares in the company, […]

BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Rating) CEO Neil Kumar sold 51,552 shares of BridgeBio Pharma stock in a transaction that occurred on Wednesday, May 17th. The stock was sold at an average price of $14.01, for a total transaction of $722,243.52. Following the completion of the sale, the chief executive officer now directly owns […]

Aptorum Group (NASDAQ:APM – Get Rating) and BridgeBio Pharma (NASDAQ:BBIO – Get Rating) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability. Profitability This table compares Aptorum Group and BridgeBio Pharma’s net […]

BridgeBio Pharma (NASDAQ:BBIO – Get Rating) had its price target boosted by Mizuho from $23.00 to $29.00 in a research note issued to investors on Monday, The Fly reports. A number of other equities research analysts have also recently commented on BBIO. The Goldman Sachs Group raised their price target on BridgeBio Pharma from $20.00 […]

BridgeBio Pharma (NASDAQ:BBIO – Get Rating) had its target price boosted by Mizuho from $23.00 to $29.00 in a report released on Monday, The Fly reports. A number of other analysts have also issued reports on the company. The Goldman Sachs Group raised their price target on BridgeBio Pharma from $20.00 to $28.00 and gave […]

BridgeBio Pharma (NASDAQ:BBIO – Get Rating) posted its quarterly earnings results on Thursday. The company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.09), Briefing.com reports. The business had revenue of $1.83 million during the quarter, compared to analysts’ expectations of $3.23 million. During the same quarter […]

BridgeBio Pharma (NASDAQ:BBIO – Get Rating) issued its quarterly earnings results on Thursday. The company reported ($0.92) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.09), Briefing.com reports. The business had revenue of $1.83 million for the quarter, compared to the consensus estimate of $3.23 million. The company’s revenue was […]

Fernwood Investment Management LLC trimmed its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Rating) by 0.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 203,000 shares of the company’s stock after selling 1,550 shares during the period. […]

Pinnacle Wealth Management Advisory Group LLC reduced its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Rating) by 6.9% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 43,500 shares of the company’s stock after selling 3,237 shares during the period. Pinnacle Wealth Management Advisory […]

BridgeBio Pharma (NASDAQ:BBIO – Get Rating) and Oncorus (NASDAQ:ONCR – Get Rating) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, risk, valuation, dividends and profitability. Risk and Volatility BridgeBio Pharma has a beta of 0.71, indicating […]